Jaguar Health (JAGX) Aktievy
Jaguar Health, Inc. är ett läkemedelsföretag i kommersiell fas som fokuserar på att utveckla växtbaserade receptbelagda läkemedel för människor och djur med mag- och tarmproblem. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 2/6 |
| Utdelningar | 0/6 |
JAGX Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Jaguar Health, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$0.78 |
| 52 veckors högsta | US$85.40 |
| 52 veckors lägsta | US$0.72 |
| Beta | -0.053 |
| 1 månads förändring | -63.91% |
| 3 månaders förändring | -80.02% |
| 1 års förändring | -98.92% |
| 3 års förändring | -99.90% |
| 5 års förändring | -99.90% |
| Förändring sedan börsintroduktionen | -99.90% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 25
JAGX: Corporate Transactions And Nasdaq Compliance Will Drive Future Upside Repricing
The analyst price target for Jaguar Health is unchanged at $262.50, with analysts pointing to a steady fair value estimate, the same $262.50 valuation input, and slightly adjusted assumptions for revenue growth and profit margin to support their view. What’s in the News for Jaguar Health Jaguar Health is reviewing multiple potential corporate transactions, including mergers, reverse mergers, acquisitions, partnerships, joint ventures and licensing deals, as it works toward clinical completion for a crofelemer-based drug candidate targeting rare intestinal failure diseases.Uppdatering av berättelse • Jun 06
JAGX: Nasdaq Listing Risk Will Set Up Future Upside Repricing
Narrative Update on Jaguar Health The analyst price target for Jaguar Health has been reduced by $262.50. Analysts point to sharply lower revenue growth expectations and a modestly higher projected profit margin as key reasons for the reset.Uppdatering av berättelse • May 17
JAGX: Nasdaq Delisting Risk Will Set Up Future Upside Repricing
Analysts have reset Jaguar Health's fair value estimate from $7.50 to $262.50, reflecting a revised view on the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Nasdaq staff issued a delisting notice on May 1, 2026, citing Jaguar Health's publicly held shares of common stock of approximately 401,226 after the 1 for 35 reverse stock split, which is below the 500,000 minimum required for continued listing under Nasdaq Listing Rule 5550(a)(4) (Nasdaq notice).Recent updates
Uppdatering av berättelse • Jun 25
JAGX: Corporate Transactions And Nasdaq Compliance Will Drive Future Upside Repricing
The analyst price target for Jaguar Health is unchanged at $262.50, with analysts pointing to a steady fair value estimate, the same $262.50 valuation input, and slightly adjusted assumptions for revenue growth and profit margin to support their view. What’s in the News for Jaguar Health Jaguar Health is reviewing multiple potential corporate transactions, including mergers, reverse mergers, acquisitions, partnerships, joint ventures and licensing deals, as it works toward clinical completion for a crofelemer-based drug candidate targeting rare intestinal failure diseases.Uppdatering av berättelse • Jun 06
JAGX: Nasdaq Listing Risk Will Set Up Future Upside Repricing
Narrative Update on Jaguar Health The analyst price target for Jaguar Health has been reduced by $262.50. Analysts point to sharply lower revenue growth expectations and a modestly higher projected profit margin as key reasons for the reset.Uppdatering av berättelse • May 17
JAGX: Nasdaq Delisting Risk Will Set Up Future Upside Repricing
Analysts have reset Jaguar Health's fair value estimate from $7.50 to $262.50, reflecting a revised view on the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Nasdaq staff issued a delisting notice on May 1, 2026, citing Jaguar Health's publicly held shares of common stock of approximately 401,226 after the 1 for 35 reverse stock split, which is below the 500,000 minimum required for continued listing under Nasdaq Listing Rule 5550(a)(4) (Nasdaq notice).Uppdatering av berättelse • Apr 25
JAGX: Nasdaq Listing Risk Will Set Up Future Upside Repricing
Analysts have adjusted their price target for Jaguar Health to $7.50, reflecting updated views on the company’s profit margin profile and long term P/E expectations, while keeping fair value and growth assumptions broadly in line with prior estimates. What's in the News Jaguar Health filed its 10-K on April 7, 2026, with auditor RBSM LLP issuing an unqualified opinion.Uppdatering av berättelse • Apr 10
JAGX: Nasdaq Listing Risk Will Drive Future Upside Repricing Potential
Analysts have adjusted their price target for Jaguar Health to reflect updated assumptions for slower revenue growth, largely unchanged profit margins, and a substantially higher forward P/E multiple. What's in the News Jaguar Health reported that it will be unable to file its next 10-K by the SEC deadline, indicating a delay in required financial reporting (SEC filing announcement).Uppdatering av berättelse • Mar 27
JAGX: Nasdaq Listing Risk Will Trigger Future Upside Repricing Potential
Analysts now place Jaguar Health's price target at $7.50, consistent with the prior $7.50 view. They cite broadly unchanged fair value, discount rate and revenue growth assumptions, alongside a slightly lower profit margin outlook and a modestly higher future P/E expectation.Uppdatering av berättelse • Mar 12
JAGX: Nasdaq Listing Risk Will Set Up Potential Upside Repricing
Analysts maintained their $7.50 price target for Jaguar Health, citing a higher discount rate and slightly lower assumed profit margins, partly offset by a higher future P/E assumption, as the key factors in their updated model. What's in the News On March 5, 2026, Nasdaq notified Jaguar Health that its common stock had closed below the minimum US$1.00 bid price for 30 consecutive business days, leaving the company out of compliance with Nasdaq Listing Rule 5550(a)(2) (Key Developments).Uppdatering av berättelse • Feb 25
JAGX: Short Term Funding Will Support Improved Profitability Expectations
Analysts have reset their price target for Jaguar Health from $28 to $7.50. They now apply a lower discount rate, more moderate revenue growth expectations, slightly tighter profit margin assumptions, and a higher future P/E multiple in their updated model.
Uppdatering av berättelse • Feb 09
JAGX: Recent Debt Financing Will Support Upside Potential
Analysts have slightly adjusted their fair value estimate for Jaguar Health to US$35.00. This reflects small tweaks to discount rate, revenue growth and future P/E assumptions rather than a major shift in their overall thesis.Uppdatering av berättelse • Jan 25
JAGX: Near Term Debt Funding And Shareholder Votes Will Support Upside Potential
Analysts have adjusted their price target for Jaguar Health to US$35.00, reflecting updated views on fair value, discount rate, growth assumptions and future P/E that they consider better aligned with the stock's current risk and return profile. What's in the News Jaguar Health entered into a securities purchase agreement on January 6, 2026, for unsecured promissory notes with an aggregate principal amount of US$350,000, carrying 6% annual interest and maturing one month after issuance (Key Developments).Uppdatering av berättelse • Jan 11
JAGX: Upcoming Debt Funding And Shareholder Votes Will Support Upside Potential
Analysts have slightly adjusted their fair value target for Jaguar Health to US$35.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping the headline price target level unchanged. What's in the News On November 24, 2025, Jaguar Health, Inc.Uppdatering av berättelse • Dec 26
JAGX: Future Private Placements Will Support Balance Sheet And Upside Potential
Analysts have raised their price target on Jaguar Health to 35.00 dollars, reflecting slightly higher long term revenue growth assumptions and a modestly higher discount rate. Together these factors keep fair value effectively unchanged while acknowledging incremental upside potential.Uppdatering av berättelse • Dec 12
JAGX: Future Capital Raises Will Strengthen Balance Sheet And Support Upside Potential
Analysts have modestly reduced their price target on Jaguar Health to reflect a lower fair value estimate of 35 dollars from 40 dollars, even as they factor in stronger revenue growth and a higher future price to earnings multiple, partially offset by slightly softer profit margin assumptions and a lower discount rate. What's in the News Jaguar Health closed a private placement transaction on November 24, 2025, further advancing its ongoing capital raising efforts (Key Developments).Analysartikel • Aug 29
Slammed 27% Jaguar Health, Inc. (NASDAQ:JAGX) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 27% in the...Analysartikel • Jul 02
Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 43% Hiding
The Jaguar Health, Inc. ( NASDAQ:JAGX ) share price has fared very poorly over the last month, falling by a substantial...
Ny berättelse • Apr 18
FDA And EMA Fast-Track Approvals Will Advance Orphan Treatments
New collaborations and regulatory approvals could quicken market entry, increase revenue, and improve earnings through enhanced access to global markets for orphan disease treatments.Analysartikel • Feb 05
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 30%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have had a horrible month, losing 30% after a relatively good period...Analysartikel • Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shareholders won't be pleased to see that the share price has had a very rough...Analysartikel • Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have had a horrible month, losing 27% after a relatively good period...Analysartikel • Jul 24
Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 55% in the...Analysartikel • May 24
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have retraced a considerable 49% in the last month, reversing a fair amount...Analysartikel • Mar 29
Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth
Jaguar Health, Inc. ( NASDAQ:JAGX ) shareholders are no doubt pleased to see that the share price has bounced 55% in...Analysartikel • Jan 22
Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%
Unfortunately for some shareholders, the Jaguar Health, Inc. ( NASDAQ:JAGX ) share price has dived 39% in the last...Analysartikel • Jun 10
Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 32% in the...Analysartikel • Jan 23
Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Aktieägarnas avkastning
| JAGX | US Pharmaceuticals | US Marknad | |
|---|---|---|---|
| 7D | -16.6% | 2.5% | 1.0% |
| 1Y | -98.9% | 55.5% | 18.4% |
Avkastning vs industri: JAGX presterade sämre än US Pharmaceuticals branschen som gav 55.5 % under det senaste året.
Avkastning vs Marknaden: JAGX presterade sämre än US marknaden som gav 18.4 % under det senaste året.
Prisvolatilitet
| JAGX volatility | |
|---|---|
| JAGX Average Weekly Movement | 17.8% |
| Pharmaceuticals Industry Average Movement | 9.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: JAGX s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: JAGX s veckovolatilitet ( 18% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| n/a | 47 | Lisa Conte | jaguar.health |
Jaguar Health, Inc. är ett läkemedelsföretag i kommersiell fas som fokuserar på att utveckla växtbaserade receptbelagda läkemedel för människor och djur med gastrointestinala besvär. Verksamheten bedrivs genom två segment, Animal Health och Human Health. Företaget fokuserar på att utveckla och kommersialisera receptbelagda och receptfria produkter för sällskaps- och produktionsdjur samt humanprodukter.
Jaguar Health, Inc. Sammanfattning av grunderna
| JAGX grundläggande statistik | |
|---|---|
| Börsvärde | US$458.38k |
| Vinst(TTM) | -US$50.13m |
| Intäkter(TTM) | US$29.57m |
0.0x
P/S-förhållande0.0x
P/E-förhållandeÄr JAGX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| JAGX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$29.57m |
| Kostnad för intäkter | US$4.42m |
| Bruttovinst | US$25.15m |
| Övriga kostnader | US$75.28m |
| Intäkter | -US$50.13m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -83.11 |
| Bruttomarginal | 85.06% |
| Nettovinstmarginal | -169.52% |
| Skuld/egenkapitalförhållande | -527.7% |
Hur har JAGX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/13 22:31 |
| Aktiekurs vid dagens slut | 2026/08/13 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Jaguar Health, Inc. bevakas av 2 analytiker. 0 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Robert LeBoyer | Aegis Capital Corporation |
| Christian Orquera | First Berlin Equity Research GmbH |